in vivo and translational studies

Espervita Therapeutics is focused on the discovery of metabolic reprogramming therapies, with a lead program developing first-in-class liver- and kidney-specific acetyl-CoA metabolic enzyme inhibitors. Its lead compound, EVT0185, is a first-in-class, liver- and kidney-selective inhibitor of acetyl-CoA metabolic enzymes that demonstrates broad efficacy in preclinical models—lowering blood glucose and lipid synthesis, reversing MASH and liver fibrosis, preserving kidney function, and decreasing HCC tumor burden. The company is led by a team with deep exper

Read more

drug developmentdrug discoverypreclinical studies